Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

IMPAX LABORATORIES INC (IPXL)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
04/10IMPAX LABORATORIES INC : Blog Exposure - Impax Launched a Generic Version of Est..
AC
04/10IMPAX LABORATORIES : Launches a Generic Version of Estrace Cream
AQ
04/06IMPAX LABORATORIES : Launches a Generic Version of Estrace® Cream (estradiol vag..
PU
03/30IMPAX LABORATORIES : Shareholders Approve Proposed Business Combination with Amn..
AQ
03/28IMPAX LABORATORIES, INC. (NASDAQ : IPXL) Files An 8-K Submission of Matters to a..
AQ
03/27IMPAX LABORATORIES INC : Submission of Matters to a Vote of Security Holders, Ot..
AQ
03/27IMPAX LABORATORIES : Shareholders Approve Proposed Business Combination with Amn..
PR
03/19IMPAX LABORATORIES INC : Other Events (form 8-K)
AQ
03/19IMPAX LABORATORIES : Amneal Gains Approval for Erythromycin Tablets, USP
AQ
03/19IMPAX LABORATORIES : Amneal Launches Generic for Gabitril
AQ
More news
News from SeekingAlpha
01:09aLooking For Action? S&P 1500 Most Volatile Stocks 
04/07Zuckerberg On Safari To Washington 
04/06Impax launches a generic version of Estrace cream 
03/29Looking For Action? S&P 1500 Most Volatile Stocks 
03/27Impax shareholders back merger with Amneal 
Financials ($)
Sales 2018 789 M
EBIT 2018 135 M
Net income 2018 189 M
Debt 2018 547 M
Yield 2018 -
P/E ratio 2018 23,36
P/E ratio 2019 26,27
EV / Sales 2018 2,56x
EV / Sales 2019 2,32x
Capitalization 1 470 M
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Technical analysis trends IMPAX LABORATORIES INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 21,9 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Paul M. Bisaro President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Jeffrey D. Nornhold Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC18.32%1 470
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571